nach oben

Drugs

Erschienen in:

01.06.2004 | Therapy In Practice

Management of Fatigue in Patients with Multiple Sclerosis

verfasst von: Dr Udo A. Zifko

Erschienen in: Drugs | Ausgabe 12/2004

Einloggen, um Zugang zu erhalten

Abstract

As long as no causal treatment is available for multiple sclerosis (MS), and as long as only some patients with MS respond to immunomodulators, symptomatic treatment is of paramount importance. Fatigue is the most common symptom of MS and is associated with a reduced quality of life. It is described as the worst symptom of their disease by 50–60% of patients.

The first step in managing MS-related fatigue is identifying and eliminating any secondary causes. Primary fatigue syndrome can be alleviated with drug treatment in many cases. Modafinil has been shown to be effective in some studies, and amantadine is an alternative for patients who do not respond to or cannot tolerate modafinil. The nonpharmacological management of fatigue in MS includes inpatient rehabilitation and aerobic endurance exercise.

This article describes the pathophysiology, diagnosis and treatment of MS-related fatigue —the most common symptom of MS.

Compston A, Coles A. Multiple sclerosis. Lancet 2002; 359: 1227–31CrossRef

Zifko UA. Therapie der Tagesmüdigkeit bei Patienten mit Multipler Sklerose. Wien Med Wochenschr 2003; 153: 65–72PubMedCrossRef

Comi G, Leocani L, Rossi P, et al. Physiopathology and treatment of fatigue in multiple sclerosis. J Neurol 2001; 248: 174–9PubMedCrossRef

Djaidetti R, Ziv I, Achiron A, et al. Fatigue in multiple sclerosis compared with chronic fatigue syndrome: a quantitative assessment. Neurology 1996; 46: 632–5CrossRef

Krupp LB, LaRocca NG, Muir-Nash J, et al. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematodes. Arch Neurol 1989; 46: 1121–3PubMedCrossRef

Multiple Sclerosis Council for Clinical Practice Guidelines. Fatigue and multiple sclerosis: evidence-based management strategies for fatigue in multiple sclerosis. Washington, DC: Paralyzed Veterans of America, 1998

Mathiowetz V. Test-retest reliability and convergent validity of the Fatigue Impact Scale for persons with multiple sclerosis. Am J Occup Ther 2003 Jul–Aug; 57(4): 389–95PubMedCrossRef

Marte J. Katsamakis G. de Castro P. The Fatigue Descriptive Scale (FDS): a useful tool to evaluate fatigue in multiple sclerosis. Multiple Sclerosis 1999 Feb; 5(1): 10–6

Bloch KE, Schoch OD, Zhang JN, et al. German version of the Epworth Sleepiness Scale. Respiration 2000; 66: 440–7CrossRef

10.

Bakshi R, Shaikh ZA, Miletich RS, et al. Fatigue in multiple sclerosis and its relationship to depression and neurologic disability. Mult Scler 2000; 6: 181–5PubMed

11.

Zivadinov R, Zorzon M, Bosco A, et al. Sexual dysfunction in multiple sclerosis, II: correlation analysis. Mult Scler 1999; 5: 428–31PubMed

12.

Dickinson CJ. Chronic fatigue syndrome: aetiological aspects. Eur J Clin Invest 1997; 27: 257–67PubMedCrossRef

13.

Schwartz RB, Garada BM, Komaroff AL. Detection of intracranial abnormalities in patients with chronic fatigue syndrome: comparison of MR imaging and SPECT. Am J Roentgenol 1994; 162: 935–41

14.

Filippi M, Rocca MA, Colombo B, et al. Functional magnetic resonance imaging correlates of fatigue in multiple sclerosis. Neuroimage 2002; 15(3): 559–67PubMedCrossRef

15.

Roelcke U, Kappos L, Lechner-Scott J, et al. Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study. Neurology 1997; 48: 1566–71PubMedCrossRef

16.

Sheean GL, Murray NMF, Rothwell JC, et al. An electrophysiological study of the mechanism of fatigue in multiple sclerosis. Brain 1997; 120: 299–315PubMedCrossRef

17.

Rice CL, Volmer TL, Bigland-Ritchie B. Neuromuscular responses of patients with multiple sclerosis. Muscle Nerve 1992; 15: 1123–32PubMedCrossRef

18.

Garland SJ, Lavoie BA, Brown WF. Motor control of the diaphragm in multiple sclerosis. Muscle Nerve 1996; 19: 654–6PubMedCrossRef

19.

Kesselbrenner L, Akselrod S, Ahiron A, et al. Is fatigue in patients with multiple sclerosis related to autonomic dysfunction? Clin Auton Res 2000; 10: 169–75CrossRef

20.

Sharma KR, Kent-Braun J, Mynhier MA, et al. Evidence of an abnormal intramuscular component of fatigue in multiple sclerosis. Muscle Nerve 1995; 18: 1403–11PubMedCrossRef

21.

Zimmermann C, Hohlfeld R. Fatigue bei Multipler Sklerose. Nervenarzt 1999; 70: 566–74PubMedCrossRef

22.

Modafinil for the treatment of pathological somnolence in narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group. Ann Neurol 1998; 43: 88–97CrossRef

23.

Damian MS, Gerlach A, Schmidt F, et al. Modafinil for excessive daytime sleepiness in myotonic dystrophy. Neurology 2001; 56: 794–6PubMedCrossRef

24.

Happe S, Pirker W, Sauter C, et al. Successful treatment of excessive daytime sleepiness in Parkinson’s disease with modafinil. J Neurol 2001; 248: 632–4PubMedCrossRef

25.

Pack AI, Black JE, Schwartz JRL, et al. Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea. Am J Respir Crit Care Med 2001; 164: 1675–81PubMed

26.

Kroencke D, Lynch SG, Denney DR. Fatigue in multiple sclerosis: relationship to depression, disability, and disease pattern. Mult Scler 2000; 6: 131–6PubMed

27.

Hughes RJ, vanDongen H, Dinges DF, et al. Modafinil improve alertness an performance during simulated night work [abstract no. 336E]. Sleep 2002; 24: A200

28.

Rammohan KW, Rosenberg JH, Lynn DJ, et al. Efficacy and safety of modafinil (Provigil®) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry 2002; 72: 179–83PubMedCrossRef

29.

Zifko UA, Rupp M. Erfolgreiche Behandlung der Tagesmüdigkeit bei multipler Sklerose mit Modafinil: ein Fallbericht [abstract]. Neuropsychiatry 2000; 14: 154

30.

Zifko UA, Rupp M, Schwarz S, et al. Modafinil in treatment of fatigue in multiple sclerosis: results of an open-label study. J Neurol 2002; 249: 983–7PubMedCrossRef

31.

Terzoudi M, Gavrielidou P, Heilakos G, et al. Fatigue in multiple sclerosis: evaluation and a new pharmacological approach [abstract]. Neurology 2000; 54 Suppl. 3: A61

32.

Krupp LB, Coyle PK, Doscher C, et al. Fatigue therapy in multiple sclerosis results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology 1995; 45: 1956–61PubMedCrossRef

33.

Cohen RA, Fisher M. Amantadine treatment of fatigue associated with multiple sclerosis. Arch Neurol 1989; 46: 676–80PubMedCrossRef

34.

Rosenberg GA, Appenzeller O. Amantadine, fatigue, and multiple sclerosis. Arch Neurol 1988; 14: 273–8

35.

The Canadian MS Research Group. A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. Can J Neurol Sci 1987; 14: 273–8

36.

Braňas P, Jordan R, Fry-Smith A, et al. Treatments for fatigue in multiple sclerosis: a rapid and systematic review. Health Technol Assess 2000; 4(27): 1–61PubMed

37.

Taus C, Solari A, D’Amico R, et al. Amantadine for fatigue in multiple sclerosis (Cochrane Review). Available in The Coch-rane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 3. Oxford: Update Software, 2003

38.

Weinshenker BG, Penman M, Bass B, et al. A double-blind, randomized, crossover trial of Pemolin in fatigue associated with multiple sclerosis. Neurology 1992; 42: 1468–71PubMedCrossRef

39.

Bever CT, Anderson PA, Leslie J, et al. Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients. Neurology 1996; 47: 1457–62PubMedCrossRef

40.

Sheean GL, Murray NMF, Rothwell JC, et al. An open-labelled clinical and electrophysiological study of 3,4 diaminopyridine in the treatment of fatigue in multiple sclerosis. Brain 1998; 121: 867–975CrossRef

41.

vanDiemen HA, Polman CH, vanDongen MM, et al. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double blind, cross-over study. Ann Neurol 1991; 32: 123–30CrossRef

42.

Solari A, Uitdehaag B, Giuliani G, et al. Aminopyridines for symptomatic treatment in multiple sclerosis (Cochrane Review). Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 3. Oxford: Update Software, 2003

43.

Freeman JA, Thompson AJ. Inpatient rehabilitation in MS. Int Mult Scler J 1998; 5: 16–23

44.

Freeman JA, Langdon DV, Hobart JC, et al. The impact of inpatient rehabilitation on progressive multiple sclerosis. Ann Neurol 1997; 42: 236–44PubMedCrossRef

45.

Kidd D, Thompson AJ. A prospective study of neurorehabilitation in multiple sclerosis. J Neurol Neurosurg Psychiatry 1996; 62: 423–4CrossRef

46.

Solari A, Filippini G, Gasco P, et al. Physical rehabilitation has a positive effect on disability in multiple sclerosis patients. Neurology 1999; 52: 57–62PubMedCrossRef

47.

Carey RG, Seibert JH. Who makes the most progress in inpatient rehabilitation?: an analysis of functional gain. Arch Phys Med Rehabil 1988; 9: 337–43

48.

Petajan JH, Gappmaier E, White AT, et al. Impact of aerobic training on fitness and quality of life in multiple sclerosis. Ann Neurol 1996; 39: 432–41PubMedCrossRef

49.

Richards TL, Lappin MS, Acosta-Urquidi J, et al. Double-blind study of pulsing magnetic field effects on multiple sclerosis [published erratum appears in J Altern Complement Med 1997; 3(2): 205]. J Altern Complement Med 1997; 3: 21–9PubMedCrossRef

50.

Sandroni P, Walker C, Starr A. Fatigue in patients with multiple sclerosis: motor pathway conduction and event-related potentials. Arch Neurol 1992; 49: 517–24PubMedCrossRef

51.

Sandyk R. Treatment with weak electromagnetic fields improves fatigue associated with multiple sclerosis. Int J Neurosci 1996; 84: 177–86PubMedCrossRef

Titel: Management of Fatigue in Patients with Multiple Sclerosis
verfasst von: Dr Udo A. Zifko
Publikationsdatum: 01.06.2004
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 12/2004
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200464120-00003

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2004

Somatropin (Zorbtive™)

The Role of Sulphonylureas in the Management of Type 2 Diabetes Mellitus

Somatropin Zorbtive™

Role of Fluoroquinolones in the Treatment of Serious Bacterial Urinary Tract Infections

Recent Advances in Understanding the Pathogenesis of Polycystic Kidney Disease

Immunosuppression for Long-Term Maintenance of Renal Allograft Function